Nancy Nixon MD, FRCPC

Dr. Nixon is involved in clinical, translational, and health services research. Within the health services realm, since completing the James Lind Alliance study for metastatic breast cancer in 2017, she has started patient priority projects for young women with breast cancer, and for patients with early-stage colon cancer in Canada. In 2019 she received funding as the primary investigator for an investigator-initiated trial (IIT) looking at the utility of electronic patient-reported outcomes for symptom monitoring. Within the clinical and translational realms, in 2019 she secured funding as co-investigator for a phase 2 clinical IIT evaluating a novel immune therapy combination in triple-negative breast cancer.

She will serve as the primary investigator on the translational correlative aspects for this study with local funding. Since 2018 she has been a co-investigator on a study looking at early blood markers of bone recurrence in breast cancer patients, a project that has been granted both an early cancer detection initiative grant and a Canadian Institute of Health Research (CIHR) grant. She is currently the primary investigator on two studies that are ongoing, one prospective study looking at the effect of the cdk4/6 inhibitor palbociclib on bone turnover, and a second retrospective study evaluating the tumor immunobiome of patients with HER2-positive breast cancer.